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 An oral route of drug administration is most preferred rout of delivery, as it is convenient and 
ease of ingestion. One of the disadvantages of this rout is low bioavailability, as most of the 
drugs have poor solubility in water. In the case of poorly water-soluble drugs (BCS Class II 
and IV), dissolution is the rate-limiting step in the process of drug absorption. Cyclodextrins 
are widely used for to improve the physicochemical and pharmaceutical properties such as 
solubility, stability, and bioavailability of poorly soluble drug molecules. Glimepiride, is an 
antidiabetic drug, has poor solubility in water (BCS class II).The phase solubility studies were 
carried out to study the effect of cyclodextrins according to the method described by Higuchi 
and Connors. The phase solubility studies indicated formation of Glimepiride-β-CD inclusion 
complexes at 1:1 M ratio in phosphate buffer p
H
 6.8, p
H
 7.2 and p
H
 7.4,with stability constant 
of 319.79 M
-1
, 518.23 M
-1
and 272.82 M
-1
respectively. Similarly, the phase solubility studies 
indicated the formation of Glimepiride-HP-β-CD inclusion complexes at 1:1 M ratio in 
phosphate buffer p
H
 6.8, p
H
 7.2 and p
H
 7.4 with stability constant of 342.41 M
-1
, 985.42 M
-1
 
and 226.21 M-1respectively. The statistical analysis indicated that, solubility of Glimepiride 
was markedly enhanced by complexation with β-CD and HP-β-CD in different pH. An 
inclusion complex of glimepiride with HP- β-CD was found to be more stable than β-CD at 
p
H 
7.4. 
Please cite this article in press as Chopade Tanaji Abhiman et al. Phase Solubility Studies of Glimepiride with Β-Cyclodextrin 
And Hydroxy Propyl-Β-Cyclodextrin in Different pH. Indo American Journal of Pharmaceutical Research.2017:7(08). 
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INTRODUCTION 
Solubility 
Solubility is a property of a solid, liquid, or gaseous chemical substance, which is called as solute to dissolve in a solid, liquid, 
or gaseous solvent to form a homogenous solution of the solute in the solvent. The solubility of a substance fundamentally depends on 
the solvent used as well as on temperature and pressure.[1,2,3]. The solubility of a drug is described in various descriptive terms which 
is based on the amount of drug dissolved in solvent and discussed in Table 1.
 
 
Table1. Definition of Solubility. 
 
Descriptive terms Approximate volume of solvent in milliliters per gram of solute 
Very soluble                 Less than 1 
Freely soluble                 From 1 to 10 
Soluble                 From 10 to 30 
Sparingly soluble                 From 30 to 100 
Slightly soluble                 From 100 to 1000 
Very slightly soluble                 From 1000 to 10,000 
Insoluble                 More than 10,000 
 
Need of Solubility  
As most of the drugs have poor solubility in water, low bioavailability is one of the major disadvantages of oral rout of drug 
administration. In the case of poorly water-soluble drugs, dissolution is the rate-limiting step in the process of drug absorption. When 
an active agent is administered orally, it must first dissolve in gastric and/or intestinal fluids before it can permeate the membranes of 
the GIT to reach systemic circulation and hence two areas of pharmaceutical research that focus on improving the oral bioavailability 
of active agents include; enhancing of solubility and dissolution rate of poorly water soluble drugs.[2 - 4]The biopharmaceutical 
classification system (BCS) is a scientific framework for classifying a drug substance based on its aqueous solubility and intestinal 
permeability. An aqueous solubility is the rate limiting step is drug release from the dosage form and solubility in gastric fluid for 
active agents classified under the BCS class II and IV. So increasing the solubility is an important challenge to increase the 
bioavailability for BCS class II & IV drugs.[5,6]BCS Classification System with examples of different drug is discussed in Table 2. 
 
Table 2: Biopharmaceutical Classification System. 
 
BCS CLASS SPECIFICATION EXAMPLES 
BCS Class I High Solubility  High Permeability Β-blockers Propranolol, Metoprolol 
BCS Class II Low Solubility High Permeability NSAID’s Ketoprofen, Glimepiride, Glipizide 
Antiepileptic Carbazepine 
BCS Class III High Solubility Low Permeability Β blockers Atenolol, H2 antagonist Ranitidine 
BCS Class IV Low Solubility Low Permeability Diuretics Hydrochlorothiazide, frusemide 
 
 Glimepiride chemically, shown in figure 1, is 3-ethyl-4-methyl-N-[2-[4-[(4-methylcyclohexyl) carbamoyl- sulfamoyl] 
phenyl] ethyl]-2-oxo-5H-pyrrole-1-carboxamide is a third generation sulfonylurea derivative which is commonly used in the treatment 
of non-insulin dependent Type 2 diabetes mellitus.[7-10], According to biopharmaceutical classification system (BCS) it belong to 
class- II, and pKa is 6.2, showing small intestine as the major absorption site.[5,11,12] 
 
 
 
Figure No.1. Structure of Glimepiride. 
 
 Cyclodextrins (CDs) are cyclic a-1, 4 linked oligosaccharides of a-D-glucopyranose units that have relatively hydrophobic 
central cavity and hydrophilic outer surface. Cyclodextrins are classical examples of compounds that form inclusion complexes. [13-
15]They are widely used for to improve the physicochemical and pharmaceutical properties such as solubility, stability, and 
bioavailability of poorly soluble drug molecules. They consists lipophilic inner cavity and hydrophilic outer surface, which are 
capable of interacting with a large variety of guest molecules by forming non-covalent inclusion complexes.[16-18] 
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Figure No.2. The chemical structure (a) and the toroidal shape (b)of the β-cyclodextrin molecule. 
 
Ethiraj T et al (2013) improved solubility of Glimepiride by sing urea and PVP by nano-precipitation method.[19]Gill B et al 
used Poloxamer 188  for  enhance solubility of Glimepiride [20]while Rajpurohit VS etal used PEG 6000 and PVP K25 (as carrier) by 
used to make solid dispersions of glimepiride.[21]Poor aqueous solubility and slow dissolution rate of glimepiride lead to non-
reproducible clinical response and/ or therapeutic failure in some cases due to sub therapeutic plasma drug levels. The rationale of this 
study was to improve the solubility by inclusion complexation with β-CD and HP-β-CD in different pH to improve biological 
performance of the drug. 
 
Phase Solubility Study 
 
 
Figure No. 3. Phase-solubility profiles and classification of complexes. 
 
Higuchi and Connors [22] have classified complexes based their effect on substrate solubility as indicated by phase-solubility 
profiles (Figure 3). A-type phase-solubility profiles are obtained when the solubility of the substrate (i.e., drug) increases with 
increasing legend (i.e., cyclodextrin) concentration. When the complex is first order with respect to legend and first or higher order 
with respect to substrate then AL-type phase-solubility profiles are obtained. If the complex is first order with respect to the substrate, 
but second or higher order with respect to the legend then AP-type phase-solubility profiles are obtained. AN-type phase-solubility 
profiles can be difficult to interpret. The negative deviation from linearity may be associated with cyclodextrin induced changes in the 
dielectric constant of the aqueous complexation media, changes in complex solubility or self-association of cyclodextrin molecules. 
B-type phase-solubility profiles indicate formation of complexes with limited solubility in the aqueous complexation 
medium. In general, the water-soluble cyclodextrin derivatives form A-type phase-solubility profiles, whereas the less soluble natural 
cyclodextrins frequently form B-type profiles. Most drug/cyclodextrin complexes are thought to be inclusion complexes, but 
cyclodextrins are also known to form non-inclusion complexes and complex aggregates capable of dissolving drugs through micelle-
like structures. 
The most common type of complex is the 1:1 drug/cyclodextrin complex (D/CD) in which one drug molecule (D) forms a 
complex with one cyclodextrin molecule (CD): K1:1 
 
D + CD ↔ D/CD 
 
Under such conditions an AL-type phase-solubility diagram, with slope less than unity, would be observed, and the stability 
constant (K1:1) of the complex can be calculated from the slope and the intrinsic solubility (S0) of the drug in the aqueous 
complexation media (i.e., drug solubility when no cyclodextrin is present): 
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K1:1 = Slope/[S0(1 - Slope)] 
 
The value of K1:1 is most often between 50 and 2000 M-1 with a mean value of 129, 490 and 355 M-1 for α-, β- and γ-
cyclodextrin, respectively [12,29-31]. For 1:1 drug/cyclodextrin complexes the complexation efficiency (CE) can be calculated from 
the slope of the phase-solubility diagram: 
 
CE = [D/CD] / [CD] = S0 • K1:1 = Slope/(1 - Slope) 
 
 During formulation work, it can be more useful to compare the CE than K1:1 value, while selecting cyclodextrins or 
complexation conditions[23-25].  
 The objective of present research was to study the solubility of glimepiride  at different p
H
 in presence of β- cyclodextrin and 
hydroxypropyl- β- cyclodextrin and hence to make improvement  in dissolution rate and bioavailability. 
 
MATERIALS AND METHOD 
Materials 
Glimepiride was the gift sample from Ipca Pharmaceuticals Lab Mumbai. β-cyclodextrin and hydroxy propyl β-cyclodextrin 
were purchased from Yarrow Chem Product Mumbai. All other materials used are of pharmacopoeial grade. 
 
Method 
Calibration Curve of Glimepiride 
Accurately weighed Glimepiride (100mg) was and transferred to 100ml volumetric flask and dissolved in phosphate buffer 
solution (pH 6.8, 7.2 or 7.4).  The final volume was adjusted up to 100 ml with the respective phosphate buffer solution to get first 
stock solution (FSS). One milliliter of  FSS  (1000 mcg/ml) was transferred to another volumetric flask and diluted with respective 
buffer solution up to 100 ml to get second stock solution (SSS). Further, 1 ml,2 ml,3 ml,4 ml, 9 ml of second stock solution diluted up 
to 10 ml to get the solutions corresponding to 1 μg/ml, 2 μg/ml,3 μg/ml,4 μg/ml 9 μg/ml and the absorbance were recorded at 228 nm 
by spectrophotometrically using respective buffer solution as blank (Shimadzu Double Beam Spectrophotometer-Model- UV 1700). 
The calibration curve was plotted using absorbance verses concentration and regression coefficient were calculated from the straight 
line equation.[26, 27] 
 
Phase Solubility Studies of Glimepiride 
Phase solubility studies of Glimepiride (GMP) in presence of β cyclodextrin (β-CD) and hydroxypropyl- β-cyclodextrin (HP- 
β -CD) was performed according to the method described by Higuchi and Connors. An excess amount of Glimepiride (50mg) was 
added to glass containers (10 ml), containing ß-cyclodextrin (β-CD) and hydroxypropyl- ß-cyclodextrin (HP-β-CD) in buffer media of 
different p
H
 6.8, 7.2, 7.4. The concentration of ß-cyclodextrin (β-CD) and hydroxypropyl- ß-cyclodextrin (HP-β-CD) in solution were 
ranging from 0 to 0.01 mol. The containers were shaken  at 30 RPM for 72 hours at room temperature on a rotary flask shaker 
(TARSON make Test Tube Mixer) (Figure 4 ) to achieve equilibrium. After 72 hrs of shaking solutions were filtered using nylon 
filter and one ml of filtrate was diluted suitably with buffer. The solutions were subjected for glimepiride (GMP) content by UV 
spectroscopy method at 228 nm using same concentration β cyclodextrin (β-CD) and hydroxypropyl- β-cyclodextrin (HP- β -CD) in 
phosphate buffer 7.4, 7.2 and 6.8 p
H
 as blank. The phase solubility diagram was constructed by plotting the dissolved glimepiride 
against respective concentration of ß-CD. The binding constant Kc was calculated from phase solubility diagram using its slope and 
intercept values using equation  
 
Kc=Slope/So (1-Slope) 
 
Where, Kc is apparent stability constant, Sois solubility of drug without cyclodextrin, M is molar concentration. The results 
are given in Table 6, and shown in Fig.6 and 7. 
 
 
 
Figure No. 4.  Phase solubility study on Rotospin Rotary Shaker. 
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RESULTS AND DISCUSSION 
Calibration curve of Glimepiride  
The calibration curve Glimepiride in different buffers was prepared by measuring the absorbance in phosphate buffers p
H
 6.8, 
p
H
 7.2, and p
H
 7.4. The graph of concentration (μg/ml) versus absorbance showed the linearity over the concentration range of 1 - 10 
μg/ml. The regression coefficients (R2) for straight line were found to be   0.9974, 0.9978 and 0.9987 for phosphate buffers pH 6.8, pH 
7.2, and p
H
 7.4 respectively.  The absorbances of the solutions measured at the wavelength 221.0 nm and are shown in Table 3.  
 
Table No. 3 Absorbance of glimepiride at 228 nm in different solvent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No.5. Calibration curve of Glimepiride. 
 
Phase solubility study of glimepiride in different pH with β-Cyclodextrin and hydroxypropyl β-Cyclodextrin 
The phase solubility study of Glimepiride in phosphate buffer p
H
 6.8, 7.2, and 7.4 containing β-CD and HP β-CD, was carried 
out according to the method described by Higuchi and Conner’s. The phase solubility diagrams were drawn by plotting the graph of 
amount of glimepiride solubilized verses concentration of respective cyclodextrin (Figure 6 and 7). The apparent stability constant 
(Kc) and complexation efficiency (CE) were calculated from the linear plot of the phase solubility diagram and according to the 
equation. 
                            (1) 
                                (2) 
 
Where, So = solubility of the drug in absence of β-CD and HP β-CD. 
 
 
 
 
 
Sr. No. Concentration of Glimepiride (µg/ml) Absorbance at p
H
 
p
H
 6.8 p
H 
7.2 p
H
 7.4 
1 0 0 0 0 
2 0.001 0.0615 0.051 0.059 
3 0.002 0.107 0.0966 0.093 
4 0.003 0.152 0.142 0.147 
5 0.004 0.196 0.189 0.195 
6 0.005 0.2525 0.239 0.26 
7 0.006 0.294 0.287 0.31 
8 0.007 0.3715 0.331 0.355 
9 0.008 0.402 0.372 0.41 
10 0.009 0.443 0.41 0.45 
11 0.01 0.493 0.4433 0.51 
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In all three buffer solutions, p
H
 6.8, 7.2 and 7.4 aqueous solubility of glimepiride was increased linearly with increase in 
concentration of β-CD and HP β-CD (Table 4 and 5). According to Higuchi and Connors, phase solubility diagrams can be classified 
as type AL and increase in solubility was due to the formation of a 1:1molar complex in solution as the straight line had a slope less 
than unity in each case.[22] The minimum solubility of glimepiride in presence of β-CD at pH 6.8, 7.2, 7.4 was found to be 0.000426, 
0.000364, 0.001017 mg/ml whereas the maximum solubility was found to be 0.001565, 0.002008, 0.0031mg/ml. Similarly, minimum 
solubility of glimepiride in presence of HP-β-CD at pH 6.8, 7.2, 7.4 was found to be 0.000426, 0.000364, 0.001015 mg/ml and the 
maximum solubility were found to be 0.001727,0.002953,0.003181mg/ml respectively. 
The apparent stability constant (Kc) was calculated from the linear plot of the phase solubility diagram according to the 
equation 1. The values of apparent stability constant (Kc) of Glimepiride-β-CD inclusion complexes in phosphate buffer pH 6.8, pH 7.2 
and p
H
 7.4 were found to be 319.79, 518.23 and 272.82 M
-1
 and values of apparent stability constant (Kc) of Glimepiride-HP-β-CD 
inclusion complexes in phosphate buffer p
H
 6.8, p
H
 7.2 and p
H
 7.4 were found to be 342.41, 985.42 and 226.21 M
-1
 respectively (Table 
6). The Kc values in the range of 100-1000M
-1
 indicate stronger interactions between the guest molecules (drug) and host molecules 
(β-CD or HP β-CD).The value of stability constants indicated that the complex formed between glimepiride-β-CD and glimepiride- 
HP β-CD are stable in all cases. [16, 17]. 
When results were analyzed statistically, indicated that at p
H
 6.8 and 7.2 the solubility of glimepiride was significantly 
increased in presence of HP-β-CD than β-CD (student t test P values 1.2885 x 10-5 and 0.0012). The effect of pH on the solubility of 
glimepiride in presence of β-CD and HP-β-CD was analyzed by applying one way ANOVA and the result showed that there is 
significant effect of pH on solubility of glimepiride (P=0.00022 for  β-CD and P=0.008 for HP-β-CD). The p values also suggest that 
there is a significant effect of change in p
H
 in case of β-CD than HP-β-CD. 
 
Table No. 4 Observation of phase solubility study of Glimepiride with β-CD. 
 
Sr. 
No. 
β-cyclodextrin concentration (Mol) Solubility of glimepiride (mg/ml) in different  pH 
p
H
 6.8 p
H
 7.2 p
H
 7.4 
1 0 0.000426 0.000364 0.001017 
2 0.001 0.000467 0.000608 0.001096 
3 0.002 0.000569 0.000831 0.001469 
4 0.003 0.000772 0.000964 0.001548 
5 0.004 0.000873 0.001075 0.001823 
6 0.005 0.000955 0.001208 0.002235 
7 0.006 0.001077 0.00132 0.002392 
8 0.007 0.001239 0.00145 0.00253 
9 0.008 0.001361 0.001786 0.002707 
10 0.009 0.001463 0.001897 0.002903 
11 0.01 0.001565 0.002008 0.0031 
 
 
 
Figure No. 6. Solubility study of GMP with β-CD. 
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Table No. 5 Observation of phase solubility study of Glimepiride with HP-β-CD. 
 
Sr. 
No. 
Hydroxypropyl-β-Cyclodextrin Concentration Mol) Solubility of glimepiride (mg/ml) in different pH 
p
H
 6.8 p
H
 7.2 p
H
 7.4 
1 0 0.000426 0.000364 0.001015 
2 0.001 0.000548 0.000675 0.001172 
3 0.002 0.000714 0.000905 0.001486 
4 0.003 0.000904 0.001152 0.001723 
5 0.004 0.001016 0.001408 0.001911 
6 0.005 0.001158 0.001786 0.002118 
7 0.006 0.001221 0.002031 0.002275 
8 0.007 0.001361 0.002308 0.002491 
9 0.008 0.001483 0.002564 0.002668 
10 0.009 0.001565 0.00272 0.002884 
11 0.01 0.001727 0.002953 0.003181 
 
 
 
Figure No.7. Solubility study of Glimepiride with HP-β-CD. 
 
Table No. 6 Solubility study of Glimepiride In different solvent at 228 nm. 
 
Sr. 
No. 
p
H
 of 
Media 
Solubility of Glimepiride in different pH with β-
Cyclodextrin 
Solubility of Glimepiride in different pH with  HP- 
β-Cyclodextrin 
KC CE KC CE 
1 6.8 319.799 0.13623 342.416 0.14587 
2 7.2 518.233 0.18864 985.428 0.3587 
3 7.4 272.827 0.27747 262.21 0.26614 
Where Kc = Apparent stability constant, CE = Complexation efficiency. 
 
CONCLUSION 
The phase solubility study of glimepiride showed AL type of graph using β-CD and HP-β-CD (0.001-0.01 M) in p
H
 6.8, p
H
 
7.2 and p
H
 7.2 phosphate buffer. So solubility of glimepiride increases with host concentration in each case. In all phase solubility 
studies HP-β-CD showed greater solubility than β-CD, and maximum solubility of glimepiride was found in pH 7.4 buffer with β-CD 
as well as HP- β-CD, and all phase solubility studies stable complexes were formed. An inclusion complex of glimepiride with HP- β-
CD was found to be more stable than β-CD at pH 7.4. 
Recommend future Research:  Inclusion complexes of glimepiride with β-CD and HP- β-CD can be further used in the 
development of modified release drug delivery system using various polymers. 
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ABBRAVATIONS  
ml - Milliliter 
Mol - Molarity 
µg - Microgram 
M
-1
 - Per mol 
hr - Hour 
Kc - Apparent stability constant 
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